GlassScriptPhysician profile
Sherry Wallmarker
NPI 1578946356
$8,080.55
in general payments reported to CMS, 2019-2025
32 companies · $2,788 in 2025
The $2,788 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.04 · 2022: $1,461 · 2023: $1,785 · 2024: $2,028 · 2025: $2,788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,492 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,491.61 |
| Education | $109.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,964.78 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,369.95 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $795.87 | 2022-2025 | Tremfya, Stelara, Simponi |
| Madrigal Pharmaceuticals | $479.36 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $327.86 | 2022-2023 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $302.13 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $287.23 | 2022-2025 | |
| Evoke Pharma, INC. | $274.65 | 2023-2024 | Gimoti |
| Takeda Pharmaceuticals U.S.A., INC. | $270.48 | 2024-2025 | Entyvio |
| Aimmune Therapeutics, INC. | $190.10 | 2024-2025 | Zenpep |
| Qol Medical, LLC | $181.96 | 2024-2025 | Sucraid, Sucraid |
| E.R. Squibb & Sons, L.L.C. | $178.03 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $172.48 | 2024 | Iqirvo, Bylvay |
| Celgene Corporation | $149.92 | 2022-2024 | Zeposia |
| Nevro Corp. | $141.40 | 2023 | Senza |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $141.38 | 2023 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Redhill Biopharma INC. | $137.81 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $132.39 | 2023-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $128.95 | 2022-2024 | Linzess |
| Pfizer INC. | $113.38 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $65.55 | 2022 | |
| Intercept Pharmaceuticals, INC. | $63.65 | 2024 | |
| Genzyme Corporation | $41.57 | 2025 | |
| Janssen Scientific Affairs, LLC | $24.83 | 2022 | |
| Eisai INC. | $22.33 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $21.12 | 2022 | |
| Braintree Laboratories, INC. | $20.21 | 2025 | Sutab, Suflave |
| Glaxosmithkline, LLC. | $19.89 | 2024 | |
| Novo Nordisk INC | $18.17 | 2025 | Wegovy |
| Bausch Health US, LLC | $18.04 | 2021 | |
| Vivus LLC | $14.60 | 2025 | Pancreaze |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Wallmarker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.